Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • inulin
Anthocyanin + Prebiotic Fiber for Type 2 Diabetes: A 60‑Day Randomised Trial Shows Improved Glucose and LDL
Posted inClinical Updates Diabetes & Endocrinology news Specialties

Anthocyanin + Prebiotic Fiber for Type 2 Diabetes: A 60‑Day Randomised Trial Shows Improved Glucose and LDL

Posted by MedXY By MedXY 08/09/2025
A double‑blind RCT of 60 patients with T2DM found a 60‑day supplement of riceberry anthocyanin plus inulin and rice bran reduced fasting glucose, HbA1c, and LDL‑C versus placebo with high adherence and no safety signals.
Read More
  • Combined Multiplex PCR and Procalcitonin Strategy Fails to Increase Antibiotic-Free Days in Critically Ill Patients with CAP: Insights from the MULTI-CAP Trial
  • The Evolving Genetic Landscape of Parkinson’s Disease: Global Prevalence, Phenotypic Correlations, and the Precision Medicine Imperative
  • Endoscopic Radial Artery Harvesting Superior to Open Technique for Hand Function and Neurologic Protection in CABG
  • Refining Patient Selection for Microaxial Flow Pumps: The DanGer Shock-like Profile as a Survival Predictor in STEMI-CS
  • Beyond Survival: Unpacking the Hemodynamic and Metabolic Benefits of Microaxial Flow Pumps in STEMI-Related Cardiogenic Shock
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality multiple myeloma nutrition obesity older adults Pediatrics Physical Activity Pregnancy prevention prostate cancer public health randomized clinical trial randomized controlled trial randomized trial SGLT2 inhibitors targeted therapy treatment type 2 diabetes weight loss women's health

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top
Sign in